Alterity Therapeutics (ATHE) Institutional Ownership $4.04 -0.01 (-0.12%) Closing price 07/3/2025 01:19 PM EasternExtended Trading$4.02 -0.02 (-0.47%) As of 07/3/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Alterity Therapeutics (NASDAQ:ATHE)CurrentInstitutional OwnershipPercentage2.14%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$182.89KNumber ofInstitutional Sellers(last 12 months)0 Get ATHE Insider Trade Alerts Want to know when executives and insiders are buying or selling Alterity Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ATHE Institutional Buying and Selling by Quarter Alterity Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/7/2025HB Wealth Management LLC37,483$129K0.0%+17.6%0.423% 2/17/2025Point72 Asset Management L.P.32,627$108K0.0%N/A0.373% 2/17/2025BNP Paribas Financial Markets8,790$29K0.0%N/A0.101% 1/15/2025HB Wealth Management LLC31,883$110K0.0%+34.1%0.436% 2/4/2022Envestnet Asset Management Inc.82,386$59K0.0%N/A0.364% 8/13/2021Renaissance Technologies LLC237,903$309K0.0%+5.9%1.052% 5/21/2021Citadel Advisors LLC65,011$94K0.0%N/A0.288% 5/19/2021Virtu Financial LLC69,905$101K0.0%N/A0.309% 5/18/2021Morgan Stanley627,907$904K0.0%+7.9%2.778% 5/18/2021Citadel Advisors LLC65,011$94K0.0%N/A0.288% 5/13/2021Renaissance Technologies LLC224,690$324K0.0%-30.1%0.994% (Data available from 1/1/2016 forward) ATHE Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ATHE shares? During the previous two years, the following institutional investors and hedge funds held shares of Alterity Therapeutics shares: HB Wealth Management LLC ($129K), and Point72 Asset Management L.P. ($108K), BNP Paribas Financial Markets ($29K).Learn more on Alterity Therapeutics' institutional investors. What percentage of Alterity Therapeutics' stock is owned by institutional investors? 2.14% of Alterity Therapeutics' stock is owned by institutional investors. Learn more on ATHE's institutional investor holdings. Which institutional investors have been buying Alterity Therapeutics' stock? The following institutional investors have purchased Alterity Therapeutics' stock in the last 24 months: Point72 Asset Management L.P. ($32.63K), HB Wealth Management LLC ($13.70K), and BNP Paribas Financial Markets ($8.79K). How much institutional buying is happening at Alterity Therapeutics? Institutional investors have bought a total of 55,117 shares in the last 24 months. This purchase volume represents approximately $182.89K in transactions. Related Companies ALEC Institutional Ownership ACOG Institutional Ownership INMB Institutional Ownership ACTU Institutional Ownership CGEN Institutional Ownership FATE Institutional Ownership KYTX Institutional Ownership BDTX Institutional Ownership VXRT Institutional Ownership LXEO Institutional Ownership This page (NASDAQ:ATHE) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | SponsoredRevealed: NEW A.I. revolution (nobody is talking about)Nvidia's CEO says this is: "The next wave of A.I." We're at the cusp of a new "A.I. Upgrade" that is set to...Behind the Markets | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alterity Therapeutics Limited - Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Alterity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
